Biosite Announces License Agreement for Novel Diagnostic Targets

Biosite, a research-based provider of novel, rapid medical diagnostics, has exercised a semi-exclusive license for research and diagnostic purposes to a proprietary target, and has received an exclusive option to obtain licenses for 50 other diagnostic targets, under its collaboration and license agreement with Incyte. Under the agreement, Biosite is permitted to use the additional 50 target proteins, and antibodies that bind to those proteins, for research purposes.

ArriveNet (http://press.arrivenet.com/bus/article.php/579574.html)